A growing standoff in the Strait of Hormuz is endangering the flow of generic drugs to the United States, with half of all such prescriptions manufactured in India and dependent on the waterway. Limited prescription stockpiles raise concerns over potential shortages and rising healthcare costs.
- Half of U.S. generic drug prescriptions are manufactured in India
- India’s drug shipments to the U.S. transit the Strait of Hormuz
- Prescription stockpiles are limited, increasing vulnerability to disruption
- Geopolitical tensions in the Strait of Hormuz threaten supply chain continuity
- ^VIX and CL=F are sensitive to regional instability
- Potential for healthcare cost inflation due to supply risks
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.